Fig. 2From: Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cellsVemurafenib induces a feedback activation of EGFR phosphorylation in BRAF V600E thyroid carcinoma cells. a–c EGFR, phosphoEGFR, AKT, phosphoAKT, ERK and phosphoERK immunoblot analysis in BRAF V600E FRO (a), BHT101 (b) and BCPAP (c) thyroid carcinoma cell lines exposed to 10 μM PLX4032 for 4–8, 15 and 24 hBack to article page